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PSTATE-OF-THE-ART PAPER
Pulmonary Arterial Hypertension
Kelly M. Chin, MD,* Lewis J. Rubin, MD†
Dallas, Texas; and San Diego, California
Significant advances in the treatment of pulmonary arterial hypertension (PAH) have occurred over the last 10
years, starting with the approval of epoprostenol in 1998. Subsequently, multiple additional medications have
received approval, including a subcutaneous prostacyclin, an inhaled prostacyclin, and oral medications in 2
separate classes. Over this same period, the classification of pulmonary hypertension has been revised with
changes including the substitution of the term idiopathic for primary PAH and an expanded list of conditions felt
to be associated with the development of PAH. Long-term follow-up studies have provided better information on
prognosis and expected outcomes with treatment, with particularly valuable data on reassessment of prognosis
after treatment with epoprostenol. Combination therapy is more frequently being used, and limited data on
novel therapies such as stem cell transplantation have been published. The purpose of this review is to describe
the current state of evidence for the diagnosis, prognosis, and treatment of the patient with PAH. (J Am Coll
Cardiol 2008;51:1527–38) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.024l
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(ulmonary arterial hypertension (PAH) is a progressive
ondition characterized by elevated pulmonary arterial pres-
ures leading to right ventricular (RV) failure. The pulmo-
ary vascular injury underlying PAH occurs in an idiopathic
orm or in association with other disease states or exposures
nd is probably a final common response to environmental
r disease-related inciting factors coupled with genetically
etermined susceptibilities. Treatment options have ex-
anded over the last decade and now include 6 U.S. Food
nd Drug Administration–approved medications; with
hese advances, prognosis is improving. This review de-
cribes the current classification system for PAH, new
nsights into its pathogenesis and prognosis, a recent treat-
ent algorithm, and potential future therapeutic targets.
lassification of PAH
he pulmonary hypertension nomenclature has been revised
everal times, most recently in 2003. The current classifica-
ion system groups together forms of pulmonary hyperten-
ion based on similarities in their pathophysiologies and
esponses to treatment. Five major categories of pulmonary
ypertension are recognized (Table 1) (1). Group 1, PAH,
s composed of diseases in which the primary abnormality is
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8, 2007, accepted January 6, 2008.ocalized to the small pulmonary arteries. This includes
diopathic (formerly primary) PAH as well as PAH associ-
ted with other medical conditions and exposures such as
onnective tissue disease and congenital heart disease. By
efinition, patients with PAH do not have significant left
eart disease, lung disease, or chronic thromboembolic
isease and meet specific hemodynamic criteria including a
ean pulmonary arterial pressure 25 mm Hg, pulmonary
apillary wedge or left ventricular end-diastolic pressure
15 mm Hg, and pulmonary vascular resistance 3 Wood
nits.
The characteristic pathological abnormalities in the small
ulmonary arteries, ranging from intimal, medial, and
dventitial proliferation to plexogenic changes consisting of
asses of proliferating endothelial cells mixed with occa-
ional myofibroblasts and necrotizing arteritis, underscore
he notion that PAH is a vasoproliferative disease invoked
y mitogenic stimuli.
AH Subgroups
amilial PAH and hereditary hemorrhagic telangiectasia.
utations in the gene encoding the bone morphogenetic
rotein receptor type 2 (BMPR2) have been identified as
he main cause of inherited PAH, accounting for at least
0% of familial cases. Mutations have also been identified in
0% to 25% of patients with sporadic PAH and 9% of
atients with PAH associated with fenfluramine use (2).
amilial PAH is inherited as an autosomal dominant trait
ith variable penetrance and reported genetic anticipation
3). Asymptomatic carriers of the BMPR2 mutation have an
bnormal increase in pulmonary arterial pressure with exercise
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Pulmonary Arterial Hypertension April 22, 2008:1527–38(4), and it is thought that addi-
tional environmental or inherited
factors determine whether overt
disease occurs.
The BMPR2 is a transforming
growth factor-beta family recep-
tor involved in the regulation of
apoptosis and growth. Although
the exact mechanism through
which a decrease in BMPR2
signaling leads to PAH is un-
known, complete post-natal loss
of BMPR2 signaling in animal
models is sufficient to cause pul-
monary hypertension (5). Re-
uced BMPR2 expression has also been reported in the
onocrotaline animal model of acquired pulmonary hyper-
ension (6), and reduced expression of a required BMPR2
o-receptor has been described in patients with idiopathic
lassification of Pulmonary Hypertensionased on the 2003 W rld Sym osium
Table 1 Classification of Pulmonary HypertensionBased on the 2003 World Symposium
Group 1: PAH
Idiopathic
Familial
Associated with
Collagen vascular disease
Congenital systemic-to-pulmonic shunt
Portal hypertension
HIV infection
Drugs and toxins
Other: thyroid disorders, glycogen storage disease, Gaucher’s disease,
hereditary hemorrhagic telangiectasia, hemoglobinopathies,
myeloproliferative disorders, splenectomy
Associated with significant venous or capillary involvement
Pulmonary veno-occlusive disease
Pulmonary capillary hemangiomatosis
Persistent pulmonary hypertension of the newborn
Group 2: Pulmonary hypertension with left heart disease
Left-sided ventricular or atrial disease
Left-sided valvular disease
Group 3: Pulmonary hypertension associated with lung disease and/or
hypoxemia
Chronic obstructive lung disease
Interstitial lung disease
Sleep-disordered breathing
Alveolar hypoventilation disorders
Chronic exposure to high altitude
Developmental abnormalities
Group 4: Pulmonary hypertension due to chronic thrombotic and/or embolic
disease
Thromboembolic obstruction of proximal pulmonary arteries
Thromboembolic obstruction of distal pulmonary arteries
Group 5: Miscellaneous
Sarcoidosis, histiocytosis X, lymphangiomyomatosis, compression of
pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis)
Abbreviations
and Acronyms
BMPR  bone
morphogenetic protein
receptor
CHF  congestive heart
failure
HIV  human
immunodeficiency virus
NO  nitric oxide
PAH  pulmonary arterial
hypertension
RV  right
ventricle/ventricularp
dapted, with permission, from Simonneau et al. (1).
HIV  human immunodeficiency virus; PAH  pulmonary arterial hypertension.AH and other forms of acquired pulmonary hyperten-
ion (7).
Another autosomal dominant genetic disorder that at
imes leads to PAH is hereditary hemorrhagic telangiectasia
or Osler-Weber-Rendu syndrome). This disorder is char-
cterized by the development of mucocutaneous telangiec-
asias and arteriovenous malformations in the brain, lungs,
iver, and gastrointestinal tract, with wide variability in
rgans affected, even within individual families (3,8).
rugs and toxins: anorexigens, cocaine, amphetamine,
nd methamphetamine. There is an increased risk of devel-
ping PAH among patients who have taken aminorex-,
exfenfluramine-, or fenfluramine-containing appetite-
uppressant medications (9,10) and among patients with ex-
osure to stimulant medications. The precise mechanism is
nknown, but it is probably related to interactions between
hese drugs and the serotonin transporter present in both the
entral nervous system and pulmonary vasculature (11). Appe-
ite suppressants increase local levels of serotonin, a known
romoter of pulmonary vascular growth and vasoconstriction
12), by acting on this transporter through “substrate mediated
xchange.”
The interaction with and uptake of drugs into the
ulmonary artery smooth muscle cell by the serotonin
ransporter may be important, as medications that simply
lock reuptake of serotonin (selective serotonin reuptake
nhibitors) increase local levels of serotonin but have not
een associated with PAH in adults (10), do not increase
ortality in patients with established PAH (13), and unlike
he appetite-suppressant medications, do not promote
mooth muscle cell growth in vitro (14). In contrast,
aternal use of selective serotonin reuptake inhibitors has
een linked to persistent pulmonary hypertension of the
ewborn; the cause for this discrepancy remains unclear
15). The majority of patients exposed to appetite suppres-
ant medications do not develop disease and additional
enetic or environmental susceptibilities likely contribute.
Stimulants such as amphetamine, methamphetamine,
nd cocaine can also interact with the serotonin transporter
nd are also thought to lead to PAH. These drugs all have
uch stronger affinity for the dopamine and norepinephrine
ransporters, and the overall link between stimulants, the
erotonin transporter, and PAH is less well established (16).
onditions associated with PAH. Patients with connec-
ive tissue disease, congenital heart disease, portal hyperten-
ion, and human immunodeficiency virus (HIV) are at
ncreased risk of developing PAH. Risk of PAH varies, with
he highest overall risk seen among patients with certain
orms of congenital heart disease, such as a large ventricular
eptal defect or patent ductus arteriosus. Congenital heart
isease PAH patients often have higher pulmonary arterial
ressures and better cardiac output at diagnosis than pa-
ients with idiopathic PAH and, subsequently, longer sur-
ival times (17). Once overt cardiac dysfunction develops,
rognosis is much more guarded (18). Strong markers of
oor prognosis are similar to those reported in idiopathic
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April 22, 2008:1527–38 Pulmonary Arterial HypertensionAH and include high right atrial pressure and low systemic
ardiac output.
Patients with scleroderma also have very high rates of
eveloping PAH but have lower survival rates than other
AH subgroups (19). Incidence rates of approximately 30%
20) have been reported, with rates of isolated PAH highest
n patients with otherwise limited scleroderma including
hose with CREST (calcinosis, Raynaud’s phenomenon,
sophageal dysmotility, sclerodactyly, telangiectasia) syn-
rome, while those with systemic scleroderma may have
ignificant interstitial lung disease and/or significant PAH.
ther connective tissue disease patients at significantly
ncreased risk include those with lupus and mixed connec-
ive tissue disease (21).
Rates of PAH in portal hypertension patients undergoing
iver transplantation work-ups have been reported at 1% to
% (portopulmonary hypertension), and severe untreated
AH is a contraindication to transplantation (22–24).
athological changes in the pulmonary arteries appear
dentical to idiopathic PAH and are thought to relate to an
mbalance in vasoactive substances due to liver disease.
areful hemodynamic evaluation is particularly important
n these patients, as cardiac output and, at times, pulmonary
apillary wedge pressures may be elevated leading to high
ulmonary arterial pressures with normal or borderline
ulmonary vascular resistance.
Finally, PAH has been reported in approximately 0.5% of
atients infected with HIV (25). There has been no apparent
ssociation with cluster of differentiation 4 count or viral load
26), and although highly active antiretroviral therapy has
esulted in modest improvement in pulmonary pressures in
everal series (27), HIV-associated PAH, as with other forms
f PAH, generally requires treatment with medications target-
ng the pulmonary vasculature.
ulmonary Hypertension Groups II to IV
ulmonary hypertension due to left heart disease. Pa-
ients with left heart disease may develop pulmonary hyper-
ension “out of proportion” to their underlying condition
nd at times show some of the same pathological abnormalities
s patients with PAH do. These patients are classified as
aving “pulmonary venous hypertension,” and pulmonary
rtery pathological changes are generally less severe. Rec-
mmendations for treatment focus on the underlying con-
ition, with the best example of success with this strategy
oming from mitral stenosis patients undergoing successful
alloon valvotomy. Although pulmonary pressures immedi-
tely after the procedure often remained elevated, pulmonary
ressures normalized over 6 to 12 months time as long as an
cceptable improvement in left atrial pressure was achieved.
his was seen even among patients with baseline pulmonary
rterial pressures80 mm Hg, presumably due to regression of
secondary pulmonary vasculopathy (28).
Pulmonary hypertension may occur in any settinghere left-sided filling pressures are elevated, with the legree of elevation usually proportional to the pulmonary
apillary wedge pressure. Unfortunately, some patients go
n to develop right heart failure; when this occurs
urvival is poor and is more closely associated with
ulmonary artery pressure and right rather than left
entricular ejection fraction (Fig. 1) (29). In some cases,
ormalization of the left-sided filling pressures is impos-
ible, and it is tempting to use medications approved for
AH. In most cases, this should be discouraged given the
otential to worsen pulmonary vascular congestion and
he lack of clinical trial data. Epoprostenol, in particular,
hould be avoided given the apparent increase in mortal-
ty seen in congestive heart failure (CHF) patients
ithout pulmonary hypertension (30). However, small
tudies enrolling patients with CHF with reduced ejec-
ion fraction plus pulmonary hypertension have recently
een published. One study found no difference in echo-
ardiographically-determined RV systolic pressure (a
uestionable choice of end point) after 20 weeks of
osentan treatment (31); another study utilizing more typical
nd points found improved exercise capacity and hemodynam-
cs after 12 weeks of sildenafil treatment (32).
Patients with pulmonary hypertension and CHF with pre-
erved ejection fraction have not been studied in randomized
linical trials and are increasingly recognized as a cause of
levation in pulmonary pressures (33). Diagnosis is based on
ymptoms, echocardiogram, and, where necessary, right heart
atheterization (34). Treatment of diastolic CHF in general
ocuses on optimization of hypertension, rate control of atrial
brillation, and treatment of pulmonary congestion with di-
retics (35). However, once elevation in pulmonary pressures
ccurs, patients often have advanced disease where diuresis
eads to lower cardiac output and yet failure to control the
Figure 1 Survival Rates Among Patients
With CHF With Systolic Dysfunction
Survival rates without urgent heart transplantation among patients with conges-
tive heart failure (CHF) and left ventricular ejection fraction less than 35% are
lower among patients with high pulmonary arterial pressures (PAPs) and low
right ventricular ejection fraction (RVEF). Group 1: normal PAP/preserved RVEF
(n  73). Group 2: normal PAP/low RVEF (n  68). Group 3: high PAP/pre-
served RVEF (n  21). Group 4: high PAP/low RVEF (n  215). Reproduced,
with permission, from Ghio et al. (29).eft-sided filling pressures leads to worsening pulmonary hy-
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Pulmonary Arterial Hypertension April 22, 2008:1527–38ertension and right heart failure. These patients require close
onitoring and careful control of fluid balance; whether PAH
edications may be beneficial will likely be the subject of
uture clinical investigation.
ulmonary hypertension associated with lung disease
nd/or hypoxemia. Pulmonary hypertension is common in
atients with obstructive or restrictive lung disease, but in most
ases, it is relatively mild. Pulmonary arterial pressures correlate
etter with oxygen saturation than with spirometry, and for
atients who are hypoxemic at rest (PaO255 to 59 mm Hg),
reatment with continuous oxygen therapy improves survival
36). Some patients develop more severe pulmonary hyperten-
ion despite oxygen therapy, and a randomized clinical trial
nvestigating inhaled iloprost among patients with pulmonary
brosis with pulmonary hypertension is underway (37). These
atients with lung disease plus pulmonary hypertension have
ow survival rates; whether iloprost or other PAH medications
ill improve symptoms or outcomes is unknown.
ulmonary hypertension due to chronic thrombotic
nd/or embolic disease. Chronic thromboembolic pulmo-
ary hypertension is due to incomplete resolution of pulmo-
ary emboli leading to elevated pulmonary pressures and RV
ailure. Treatment of proximal thromboembolic disease is
urgical, with perioperative mortality rates at the most experi-
nced centers in the 4% to 5% range. Medical therapy is
onsidered in patients with distal thromboembolic disease who
re not operative candidates; it is also considered in patients
ho are poor surgical candidates due to comorbidities or
ccasionally in patients with severe right heart failure as a
bridge” to surgery. Limited case series and clinical trial data
uggest that medical therapy with PAH medications is better
han no therapy, but improvement is modest and should not be
onsidered a substitute for surgical treatment (38).
iagnosis
linical presentation. Most patients with PAH present
ith exertional dyspnea that progresses over months or even
ears. Exertional chest pain, syncope, and lower extremity
dema are indicative of more severe pulmonary hypertension
ith impaired right heart function. Women are affected
ore commonly than men, and patients of all ages may
evelop the disease. The mean age at diagnosis has been
eported at 36 to 50 years, with more recent series and series
ncluding associated PAH (particularly scleroderma) report-
ng older mean ages at diagnosis (39–41). Diagnosis is often
elayed due to the subtle findings on physical examination
nd the nonspecific symptoms experienced by most patients.
iagnostic evaluation. Establishing the diagnosis and eti-
logy of PAH requires a comprehensive evaluation that
ncludes pulmonary function testing, connective tissue dis-
ase serology, echocardiography, cardiac catheterization,
nd tests to exclude chronic thromboembolic disease.
Echocardiography is often the first diagnostic test to
uggest the possibility of pulmonary hypertension. The
ulmonary artery systolic pressure can be estimated nonin- casively using Doppler techniques, and when an acceptable
ricuspid regurgitant jet is obtained, these estimates show
xcellent overall correlation with invasively determined pul-
onary artery systolic pressures. However, the standard
rror of the estimate is relatively large (5 to 8 mm Hg)
42,43), and results for any individual patient should be
iewed as only an estimate of the actual pulmonary arterial
ressure and should be confirmed by right heart catheter-
zation. Other common echocardiographic findings include
ight heart chamber enlargement, paradoxical motion of the
nterventricular septum, and tricuspid insufficiency. Pericar-
ial effusions may also be visualized and, in the absence of
onnective tissue diseases, correlate with elevations in right
trial pressure (44).
Chest radiographs show enlarged central pulmonary ar-
eries and right heart dilation, and the electrocardiogram
ay show right axis deviation, RV hypertrophy, and strain.
ulmonary function testing shows either normal lung vol-
mes or mild restriction, and the diffusing capacity for
arbon monoxide is typically reduced (45).
Ventilation perfusion testing should be performed in
atients with suspected PAH to exclude surgically treatable
hronic thromboembolic pulmonary hypertension; com-
uted tomography angiography is less sensitive than venti-
ation perfusion scanning for chronic clots and should not be
sed for this purpose (46). A normal or low probability
entilation perfusion scan is typically seen in PAH, al-
hough a mottled appearance may be found. Specificity of
entilation perfusion scanning is lower than its sensitivity,
nd thus, confirmatory pulmonary arteriography is required
n those with an abnormal scan (47).
Once the diagnostic evaluation has suggested PAH, right
eart catheterization is required to confirm the presence and
o determine the severity of pulmonary hypertension, to
xclude left-sided heart disease or potentially correctable
ntracardiac left-to-right shunting, and to perform acute
asodilator testing.
Pulmonary veno-occlusive disease, an unusual form of
ulmonary hypertension, may also be considered on clinical
rounds when severe PAH accompanied by normal pulmo-
ary capillary wedge and left ventricular diastolic pressures is
ssociated with evidence of venous congestion on chest
adiograph and a patchy appearance of tracer activity on a
erfusion scan.
creening. American College of Chest Physicians guide-
ines recommend screening of patient groups at very high
isk of disease (expert-opinion level of evidence), based on
ossibly more successful outcomes among patients treated
arlier in the disease process (48). Risk groups thought to
arrant screening include patients with known genetic
utations predisposing to pulmonary hypertension, first-
egree relatives in a familial PAH family, patients with
cleroderma, patients with portal hypertension prior to liver
ransplantation, and patients with congenital systemic to
ulmonary shunts. Doppler echocardiography is the most
ommonly used screening modality; in scleroderma, serial
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April 22, 2008:1527–38 Pulmonary Arterial Hypertensionulmonary function testing with measurement of the dif-
using capacity of the lung for carbon monoxide may also be
sensitive (though not specific) indicator of pulmonary
ascular disease.
herapy
harmacologic agents used in the treatment of PAH include
alcium-channel blockers, prostanoids, endothelin antagonists,
nd phosphodiesterase type 5 inhibitors (Table 2). These
gents all have pulmonary vasodilatory effects and all except
alcium-channel blockers also have antiproliferative proper-
ies. This lack of an antiproliferative effect may explain why
nly a small subset of patients benefit from long-term
alcium-channel blocker use.
Clinical trials have included mainly patients with idio-
athic, fenfluramine-associated, and connective tissue
isease–associated PAH, but data from other PAH patient
opulations is increasing. Epoprostenol remains the treat-
ent of choice for most functional class IV patients, but oral
herapy is now usually used as initial therapy for functional
lass II and III patients (Fig. 2) (49). Decisions are generally
ade based on functional class as well as hemodynamics and
xercise capacity. Combination therapy is an area of grow-
ng research and is being used clinically either as an initial
reatment strategy or more commonly as add-on therapy
hen the response to a single medication is inadequate.
alcium-channel blockers. Calcium channel-blockers re-
ain a treatment option only for patients with a positive
asodilator challenge, as defined in Table 3. This pattern of
esponse is present in fewer than 10% of those with
diopathic PAH and even less frequently in patients with
ther forms of PAH (50). Patients whose mean pulmonary
rterial pressure remains above 40 mm Hg during a vaso-
ilator challenge despite a greater than 20% decrease are
o longer considered “responders” due to excessively high
edical Therapy for PAH
Table 2 Medical Therapy for PAH
Medication Dose
Bosentan (Tracleer) Start 62.5 mg by mouth twice daily
Increase to 125 mg twice daily after 4 weeks
Ambrisentan (Letairis) Start 5 mg by mouth daily; consider increasing to
10 mg daily if 5 mg is tolerated
Sitaxsentan (Thelin)* 100 mg by mouth daily
Sildenafil (Revatio) 20 mg by mouth 3 times daily
Beraprost* Start 20 g by mouth 4 times a day; increase in
increments of 20 g 4 times a day if tolerated
Iloprost (Ventavis) 2.5 g inhaled 6 to 9 times daily; if tolerated
increase to 5 g 6 to 9 times daily
Epoprostenol (Flolan) Initiate at 2 ng/kg/min and increase every 15 min
until dose-limiting side effects occur†
Treprostinil (Remodulin) Initiate at 1.25 ng/kg/min and increase by no more
than 1.25 ng/kg/min weekly for 4 weeks and after
that by no more than 2.5 ng/kg/min weekly
Not approved in the U.S. †Intravenous epoprostenol and treprostinil dosing vary; the epoprostenol
ackage insert goes on to say that more commonly a slower titration schedule is used. Typically
ose increases of 0.5 ng/kg/min to 1 ng/kg/min are performed initially daily and then approxi-d
ately weekly until the target dose is achieved, limited by side effects.
PAH  pulmonary arterial hypertension.ong-term failure rates. Empiric therapy without vasodilator
esting is also not recommended because most patients will
ail therapy.
Among vasodilator responders, calcium-channel blocker
herapy can be initiated with nifedipine (30 mg/day) or
iltiazem (120 mg/day) and then increased to the maximal
olerated dose. Close follow-up for continued benefit is
equired, because only 50% of patients maintain long-term
esponses.
ndothelin antagonists. Endothelin-1 is a potent vaso-
onstrictor and mitogen acting on both the systemic and
ulmonary vasculature through 2 receptors. Although it is
roduced and acts predominately locally, circulating levels
f endothelin-1 are increased in PAH and correlate with
isease severity (51). Two endothelin antagonists, bosentan
Tracleer, Actelion, Allschwil, Switzerland) and ambrisen-
an (Letairis, Gilead, Forest City, California) are approved
or use in the U.S., and a third drug, sitaxsentan (Thelin,
ncysive, Houston, Texas) is approved in Europe and
anada. Bosentan is a nonspecific endothelin antagonist,
locking both the endothelin-A receptor and the
ndothelin-B receptor, while sitaxsentan and ambrisentan
re specific for the endothelin-A receptor. All 3 are oral
gents that led to improvement in exercise capacity and
emodynamics in 12- to 16-week clinical trials (52–55).
osentan also led to improved survival versus “expected”
urvival in open label studies (56,57); long-term survival
ata from ambrisentan and sitaxsentan have been presented
nd appear to be favorable as well. The open-label extension
tudy for sitaxsentan also included a randomized but un-
linded bosentan arm; results for 6-min walk distance were
imilar between the 2 groups but time to clinical worsening
avored sitaxsentan (58).
Bosentan has been associated with increases in liver function
ests in approximately 11% of patients, while abnormalities
ith other endothelin antagonists are lower. Monthly liver
unction testing is required for patients on any endothelin
ntagonist, and increases in transaminases greater than 3
imes normal require reduction in dose or treatment inter-
uption, as described in the package inserts.
hosphodiesterase-5 inhibitors. Sildenafil (Viagra, Reva-
io, Pfizer, New York, New York) is a phosphodiesterase-5
nhibitor initially approved for erectile dysfunction but
ubsequently shown to have effects on the pulmonary
asculature. Sildenafil increases the effects of locally pro-
uced nitric oxide (NO) by inhibiting the breakdown of
O’s second messenger, cyclic guanosine monophosphate.
his results in pulmonary vasodilation and inhibition of
mooth muscle cell growth. Because this occurs only in
ascular beds with significant production of NO, sildenafil
esults in less ventilation-perfusion mismatch than epopro-
tenol. Benefits with treatment include improved symp-
oms, increased 6-min walk distance, improvement in he-
odynamics, and in the open label follow-up study, 95%
urvival at 1 year (59). The approved dose is 20 mg 3 times
aily, but doses up to 80 mg 3 times daily were studied and
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Pulmonary Arterial Hypertension April 22, 2008:1527–38re sometimes considered when the initial response is
nadequate.
rostacyclins. The PAH patients exhibit an underproduc-
ion of prostacyclin (PGI2) (60), a product of the arachi-
onic acid cascade that promotes vasodilation and inhibits
ascular proliferation and platelet aggregation. Epoproste-
ol (synthetic prostacyclin, Flolan, Gilead) was the first
ood and Drug Administration–approved therapy for
AH. Due to its short half-life, it requires delivery through
continuous portable infusion pump and an indwelling
entral venous catheter. Epoprostenol remains the treat-
Figure 2 Treatment Algorithm for PAH Adapted From 2007 ACC
Letters following recommendations are based on a combination of level of evidence a
weak recommendation. Recommendations with an E are based on expert opinion rath
monary arterial hypertension (PAH) after these guidelines were published. ACCP  Am
INH  inhaled; IPAH  idiopathic pulmonary arterial hypertension; IV  intravenous; S
asoreactivity Testing
Table 3 Vasoreactivity Testing
Responders:
Fall in mean pulmonary artery pressure of10 mm Hg to a value 40 mm Hg
Increased or unchanged cardiac output
Commonly used agents in vasoreactivity testing
Epoprostenol: infused starting at 1 to 2 ng/kg/min and increased by 2 ng/kg/
min every 5 to 10 min until a clinically significant fall in blood pressure,
increase in heart rate, or adverse symptoms (e.g., nausea, vomiting)
develop.
Adenosine: infused at 50 g/kg/min and increased every 2 min until adverse
symptoms or hypotension develop or until a dose of 200 to 250 g/kg/min is
reached.
Nitric oxide: inhaled nitric oxide is administered at 10 to 20 parts per million
for 5 min.p
atients classified as vasoresponders may be considered for therapy with calcium-channel
lockers.ent of choice for patients with the most advanced disease
nd leads to improvements in exercise capacity, hemody-
amics, and quality of life. It also appears to improve
urvival based on a 12-week randomized but unblinded
tudy (61) and 2 longer-term open-label studies (62,63).
Longer-acting prostacyclin analogs have also been devel-
ped for intravenous, inhaled, and oral use, with variable
ffectiveness and tolerability. This includes treprostinil (Re-
odulin, United Therapeutics, Silver Spring, Maryland),
pproved for subcutaneous and intravenous use in the U.S.;
loprost (Ventavis, Actelion), approved for inhaled use in
he U.S. and for intravenous and inhaled use in Europe; and
eraprost (Toray Industries, New York, New York), an oral
edication approved in Japan (64). Additional studies of
ral and inhaled treprostinil are underway with results
xpected in 2008. The inhaled route provides several ben-
fits including fewer systemic side effects and less
entilation-perfusion mismatch, though with potentially
ower efficacy.
Epoprostenol or treprostinil may be initiated at 1 to 2
g/kg/min and titrated over several days to 5 to 10 ng/kg/
in, limited by side effects and systemic hypotension.
ubsequent dose increases are usually made every 3 to 7 days
ntil the initial target dose is reached. Treprostinil appears
o require up to 2 times higher overall doses than epopro-
tenol to achieve similar effects. Excessively low doses of
idelines
ceived benefit: A  strong recommendation; B  moderate recommendation; C 
clinical trial evidence. Ambrisentan was approved for functional class II and III pul-
College of Chest Physicians; CCB  calcium-channel blocker; FC  functional class;
ubcutaneous. Reproduced, with permission, from Badesch et al. (49).P Gu
nd per
er than
erican
C  srostacyclins may be ineffective, but the earlier idea that all
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April 22, 2008:1527–38 Pulmonary Arterial Hypertensionatients require continuous uptitration of epoprostenol re-
ardless of clinical status has also been questioned as this
ay lead to excessively high cardiac output and even high
utput heart failure. Instead, frequent reassessment of
ymptoms, exercise capacity, and, in many centers, periodic
emodynamic evaluations are used to titrate to the most
ffective dose. Side effects common to all prostacyclins
nclude flushing, jaw pain, and body aches, and these may
lso limit the achievable dose.
AH subgroups. Patients with idiopathic PAH and PAH
ssociated with scleroderma (65) account for the majority of
atients enrolled in clinical trials with good evidence of
enefit in both groups. Small numbers of patients with
epaired or unrepaired congenital heart disease have also
een included in the pivotal PAH clinical trials (sitaxsentan,
ildenafil, treprostinil) and in other studies (66–68) that
howed improvement in hemodynamics, exercise capacity,
nd functional class. For HIV and portal hypertension,
ainly case-series level of evidence is available; these studies
howed improvement in hemodynamics, exercise capacity,
nd symptoms relative to baseline (69–73). Treatment has
lso allowed portopulmonary hypertension patients to un-
ergo successful liver transplantation. Current treatment
uidelines do not differentiate between PAH subgroups in
heir recommendations for initial therapy, but additional
tudies are needed.
ombination therapy. Combination therapy has been ad-
ocated based on the potential for additive or synergistic
ffects. Improvement in hemodynamics, exercise capacity,
nd symptoms over 12- to 16-week study periods has now
een reported (Table 4) (74–77), and additional studies
ncluding 1 long-term study with a morbidity/mortality end
oint are ongoing. The typical improvement in walk dis-
ance (20 to 26 m) is less than that of studies comparing
Combination Therapy in PAH
Table 4 Combination Therapy in PAH
Combination 6MWD Improv
Bosentan  inhaled iloprost
STEP trial (n  67) Peak†: 26 m (p 
Trough: no diff
COMBI trial (n  40): unblinded
randomized
No difference
IV epoprostenol  oral therapy
BREATHE-2 trial (n  33)
epoprostenol  bosentan
No difference
PACES trial (n  267)
epoprostenol  sildenafil
26 m (p  0.05)
Oral therapy  inhaled treprostinil
TRIUMPH-1 trial (n  235) Walk improveme
positive (press
results expect
In adequately powered studies, combination therapy has led to
*Improvement is placebo corrected. †Peak refers to post-inhalation, w
BREATHE-2 Bosentan Randomized Trial of Endothelin Antagonist T
in Idiopathic Pulmonary Arterial Hypertension; IV  intravenous; PACE
Intravenous Epoprostenol in PAH; PVR  pulmonary vascular resista
Combination with Bosentan for Evaluation in Pulmonary Arterial Hypertension
in Patients With Severe PAH; 6MWD  6-min walk distance; other abbreviatonotherapy to placebo, but given improvement in symp-
oms, time to clinical worsening, and hemodynamics, these
hanges appear to be clinically significant. Additionally, a
arge uncontrolled study investigating protocol-driven com-
ination therapy for patients failing to achieve certain
xercise test goals while on monotherapy reported very good
verall survival rates (93%, 83%, and 80% at 1, 2, and 3
ears), with 43% of patients requiring combination therapy
78). Combination therapy has been suggested for patients
ith signs of right heart failure, 6-min walk distance 380
and persistent functional class III or IV symptoms despite
reatment with 1 medication.
djunctive therapies: anticoagulation, digoxin, and di-
retics. Anticoagulation with warfarin has been shown in
bservational studies to improve survival, and it is recom-
ended for patients with idiopathic PAH (79). Anticoag-
lation may prevent both in situ thrombosis and pulmonary
mbolism; these events may be more common and more
erious in PAH due to abnormalities in platelet function
nd in the activated clotting system. Consideration of
nticoagulation in other PAH groups has also been sug-
ested, although this is based on expert opinion only with
ome patient groups (portopulmonary hypertension, con-
enital heart disease) at higher risk of bleeding complica-
ions. A goal international normalized ratio of either 1.5 to
.5 (80) or at some centers 2.0 to 3.0 has generally been
ecommended. Anticoagulation is also recommended for all
atients with chronic thromboembolic pulmonary hyperten-
ion; it has not been studied in patients with pulmonary
ypertension associated with left heart disease or pulmonary
ypertension associated with lung disease.
Digoxin has been used as an adjunctive treatment for
ight heart failure but with inconclusive benefits. It is also
requently used in the treatment of supraventricular arrhyth-
* (m) Other Evaluations
) Improved functional class, time to clinical
worsening, post-inhalation
hemodynamics (p  0.05)
No difference functional class, time to
clinical worsening
Trend toward greater improvement in PVR
(p  0.08)
Improved hemodynamics, time to clinical
worsening (p  0.05)
rted as
e);
8
ment in functional class, hemodynamics, and exercise capacity.
ugh was pre-inhalation.
; COMBI Combination Therapy of Bosentan and Aerosolized Iloprost
e Efficacy and Safety of Sildenafil Citrate Used in Combination With
TEP  Iloprost Inhalation Solution Safety and Pilot Efficacy Trial inement
0.05
erence
nt repo
releas
ed 200
improve
hile tro
herapy
S  Th
nce; S; TRIUMPH-1 Clinical Investigation Into Inhaled Treprostinil Sodium
ions as in Table 1.
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Pulmonary Arterial Hypertension April 22, 2008:1527–38ias as it is better tolerated than calcium-channel blockers
r beta-blockers in patients with reduced RV function.
Diuretics are often required to minimize symptoms of
yspnea and right heart failure. The excessive afterload from
ulmonary hypertension often leads to marked right ven-
ricular dilation along with compression of the left ventricle.
n this setting, fluid overload may actually reduce cardiac
utput, and patients with severe PAH and right heart failure
ay require significant doses of diuretics.
rognosis, Monitoring Response
o Therapy and Lung Transplantation
rognosis. Median survival among patients diagnosed with
AH in the U.S. between 1981 and 1985 was 2.8 years (81).
ince that time, survival has improved to the point that
atients are usually not referred for lung transplantation at
he time of diagnosis. Instead, most patients begin medical
herapy and are reassessed after at least several months of
reatment. Five-year survival among epoprostenol-treated
atients is now 47% to 55% with 70% 5-year survival
mong those improving to functional class I or II (Fig. 3)
62,63).
Although some hemodynamic improvement may be seen
mmediately after starting PAH medications, many patients
o not have a significant acute pulmonary vasodilatory
esponse. These patients usually still show improvement in
emodynamics when reassessed after several months, po-
entially due to treatment effects on growth and remodeling
n the pulmonary vasculature. Increases in walk distance and
educed symptoms begin within a few weeks of treatment
nitiation and then may plateau around 12 to 16 weeks.
Figure 3 Survival in Patients With Idiopathic
PAH After Treatment With Epoprostenol
Among patients who were FC III or IV prior to treatment with epoprostenol, sur-
vival among patients improving to FC I or II (solid line) was substantially better
than patients who were FC III or IV (dashed line) after treatment; p  0.001.
NYHA  New York Heart Association; other abbreviations as in Figure 2. Repro-
duced, with permission, from Sitbon et al. (63).cmprovement is often maintained over years, but there is
ignificant variability and subsequent deterioration is not
ncommon.
Patients who have developed signs or symptoms of right
eart failure have much lower survival rates than those with
nly elevations in pulmonary artery pressures, and most
rognostic markers measure some aspect of RV function
ither at rest or with exercise. Post-treatment markers of
oor prognosis include elevated right atrial pressure, low
ardiac index, low mixed venous oxygen saturation, contin-
ed functional class III/IV symptoms, poor exercise capac-
ty, pericardial effusion, and elevated B-type natriuretic
eptide level (56,63,82,83). The degree of elevation in
ulmonary arterial pressures can also be predictive, but this
s most important only while RV function is still relatively
ormal. Failure to show some improvement between base-
ine and follow-up in symptoms, hemodynamics, and exer-
ise capacity are also poor prognostic signs.
onitoring and lung transplantation. Frequent evalua-
ions are required to identify patients failing therapy as well
s to allow timely referral for lung transplantation. Routine
ollow-up should include assessment of symptoms, func-
ional class and exercise capacity at approximately 3-month
ntervals, and a more detailed evaluation of pulmonary
ressures and RV function on an approximately annual
asis.
The 6-min walk distance is the most commonly used test
o assess exercise capacity; it is performed using a long
allway and a pulse oximeter. Post-treatment distances
380 m are associated with a worse prognosis. Formal
ardiopulmonary exercise testing can also be used, but
ppears to be less reliable in the PAH patient population
nless performed in very experienced centers.
Assessment of RV function can be performed through
combination of echocardiogram, cardiac catheteriza-
ion, and, potentially, B-type natriuretic peptide level or
ardiac magnetic resonance imaging. Echocardiography
ust be used cautiously in tracking PAH patients, as
chocardiographic estimates of RV systolic pressure do
ot predict survival (19). Rather, echocardiographic
arkers of RV function such as right atrial size, septal
hift toward the left ventricle during diastole, and tricus-
id annular plane excursion (a correlate of RV ejection
raction) predict outcome (84).
Cardiac catheterization is performed in many patients on
n approximately annual basis, but this requirement is
ebated. Catheterization is particularly important in pa-
ients receiving an intravenous or subcutaneous prostacyclin
o avoid under- and overdosing of the medication. It should
lso be considered in most cases where add-on therapy is
lanned both to confirm the need for additional therapy and
o acquire a new “baseline” for future comparisons.
Patients with persistent functional class III or IV symp-
oms, right atrial pressure15 mm Hg, or cardiac index2
/min/m2 should be considered for lung transplantation;
ombination therapy and atrial septostomy may be consid-
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April 22, 2008:1527–38 Pulmonary Arterial Hypertensionred simultaneously. For most patients, either single- or
ouble-lung transplantation are options, but many centers
refer double-lung transplantation owing to concerns about
ost-operative reperfusion injury after single-lung trans-
lantation and slightly higher (p  0.05) long-term survival
ates with double-lung transplantation. Survival in the early
ost-operative period is lower for PAH patients than for
ther patients undergoing lung transplantation, but 5- and
0-year survival rates are similar (85). Heart-lung transplan-
ation is still sometimes performed, but more often is
eserved for patients with pulmonary hypertension associ-
ted with complex congenital heart disease that cannot be
orrected at the time of surgery.
cute Presentations: RV Failure and PAH
atients with advanced PAH may present acutely with
olume overload, marginal blood pressure, and, at times,
levated creatinine, related either to an acute process or
imply worsening RV failure. Although the “preload-
ependent RV” may respond poorly to significant volume
epletion, aggressive volume loading of the already dilated
nd overloaded RV may worsen hypotension and cardiac
utput.
This probably relates to ventricular interdependence
ather than a lack of validity of the Frank-Starling mecha-
ism. In the decompensated patient, elevated RV volume
eads to septal shift (Fig. 4), with reduced left ventricular
nd-diastolic volume and low cardiac output. The poor
esponse to volume has been shown in animal models of
cute RV failure, where fluid administration leads to lower
ardiac output, worsening septal shift, and a progressive
ownward spiral in hemodynamics (86,87).
This ventricular interdependence also explains the im-
roved cardiac output seen with atrial septostomy and may
artially explain the higher survival of PAH patients with a
atent foramen ovale or with congenital heart disease. In
his situation, the lower systemic arterial oxygen saturation
wing to right-to-left shunting is partially offset by an
ncrease in cardiac output and, in most cases, an overall
ncrease in oxygen delivery (88).
Treatment of the acutely ill patient with PAH should
nclude careful evaluation for secondary causes of decom-
ensation such as a low-grade line infection (for those on an
ntravenous therapy) or pulmonary thromboembolism.
any patients are volume overloaded at presentation, and
iuresis, even in the setting of marginal cardiac output and
ow blood pressure, may be required. In some cases, support
ith inotropes or pressors is necessary: animal data suggest
better hemodynamic response with sympathomimetic
gents such as dobutamine, norepinephrine, and dopamine
ather than vasopressin or phenylephrine; milrinone also has
avorable effects on cardiac output but may lead to excessive
ypotension (89–92). euture Therapeutic Targets
ovel pathways of potential importance in PAH. A
ariety of other substances may play roles as mediators
hrough a final common pathway of pulmonary angiogen-
sis and may therefore be appealing therapeutic targets.
hese include vasoactive intestinal polypeptide (93),
latelet-derived growth factor (94), serotonin and its recep-
ors and transporter (95), and Rho kinase inhibitors (96).
linical trials for many of these substances are underway.
tem cell replacement/transplant therapy: rebuilding the
amaged circulation. Endothelial progenitor cells have
ecently been explored as a potential source for neovascu-
arization of the diseased pulmonary circulation of PAH.
nimal data in a monocrotaline model of pulmonary
ypertension was positive, and a pilot study in 31 patients
ith PAH found improvement in 6-min walk distance and
emodynamics 12 weeks after treatment with autologous
Figure 4 Cardiac MRI in Advanced PAH
Images of idiopathic PAH in a 32-year-old subject. The “D-shaped” left ventricle
(LV) seen in panels A and B is due to elevated pulmonary pressures leading
to dilation of the right ventricle (RV). The right atrium (RA) is also markedly
dilated. The RV end-diastolic volume is 363 ml, and the RV ejection fraction is
20%. LA  left atrium; MRI  magnetic resonance imaging; other abbreviation
as in Figure 2.ndothelial progenitor cells (97). In animals, transfection of
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Pulmonary Arterial Hypertension April 22, 2008:1527–38he endothelial progenitor cells with NO synthase appears
o reduce pulmonary pressures to an even greater extent
98). Questions at this point relate to magnitude and
uration of the benefits as well as continued evaluation of
afety.
onclusions
anagement of PAH has evolved significantly over the past
ecade with now multiple effective therapies. Patients are
iving longer and more comfortable lives, and many are now
reated with oral therapies. However, there is still no cure
or PAH, and many patients remain symptomatic despite
herapy. As research in this field increases, new findings
egarding the pathogenesis of PAH are presenting potential
ew therapeutic targets. These approaches are likely to
ramatically change the management algorithm for PAH
ver the next decade. Treatment strategies that combine
edications and target multiple pathogenic pathways have
ow been demonstrated to be both safe and more effective
han monotherapy and are emerging as the preferred ap-
roach to management of many patients.
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niversity of Texas Southwestern Medical Center, 5323 Harry
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